Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs
详细信息 查看全文
- 作者：Dr Julian N. Trollor (1)
Xiaohua Chen (2)
Perminder S. Sachdev (1) (2) - 刊名：CNS Drugs
- 出版年：2009
- 出版时间：June 2009
- 年：2009
- 卷：23
- 期：6
- 页码：477-492
- 全文大小：285KB
- 参考文献：1. Delay J, Pichot P, Lemperiere T, et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris) 1960 Jan; 118(1): 145-2
2. Berardi D, Amore M, Keck Jr PE, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998 Oct 15; 44(8): 748-4 CrossRef
3. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: and analysis of 115 cases. Biol Psychiatry 1987 Aug; 22(8): 1004-0 CrossRef
4. Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand 1994 Dec; 90(6): 424- CrossRef
5. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry 1990 Sep; 147(9): 1149-5
6. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986 Apr; 73(4): 337-7 CrossRef
7. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997 Aug; 154(8): 1156-
8. Adityanjee Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999 May–Jun; 22(3): 151-
9. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989 Jan; 50(1): 18-5
10. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005 Jul–Aug; 28(4): 197-04 CrossRef
11. Levinson DF, Simpson G. Sequelae of neuroleptic malignant syndrome. Biol Psychiatry 1987 Feb; 22(2): 237- CrossRef
12. Spirko BA, Wiley II JF. Serotonin syndrome: a new pediatric intoxication. Pediatr Emerg Care 1999 Dec; 15(6): 440- CrossRef
13. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22(3): 475-3 CrossRef
14. Weller M, Kornhuber J. Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report. Aust N Z J Med 1996 Apr; 26(2): 232- CrossRef
15. Nemecek D, Rastogi-Cruz D, Csernansky JG. Atropinism may precipitate neuroleptic malignant syndrome during treatment with clozapine [published erratum appears in Am J Psychiatry 1993 Dec; 150 (12): 1910]. Am J Psychiatry 1993 Oct; 150(10): 1561.
16. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988 Dec 24-1; 2(8626-627): 1500 CrossRef
17. Tsai G, Crisostomo G, Rosenblatt ML, et al. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995 Jun; 7(2): 91- CrossRef
18. DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991 Mar; 52(3): 105-
19. Sachdev P, Kruk J, Kneebone M, et al. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995 Oct; 15(5): 365-1 CrossRef
20. Nopoulos P, Flaum M, Miller DD. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann Clin Psychiatry 1990; 2(4): 251- CrossRef
21. Goates MG, Escobar JI. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge. J Clin Psychopharmacol 1992 Apr; 12(2): 139-0 CrossRef
22. Viner MW, Escobar JI. An apparent neurotoxicity associated with clozapine. J Clin Psychiatry 1994 Jan; 55(1): 38-
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
24. Pope Jr HG, Keck Jr PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986 Oct; 143(10): 1227-3
25. Caroff SN, Mann SC, Lazarus A, et al. Neuroleptic malignant syndrome: diagnostic issues. Psychiatr Ann 1991; 21: 130-7
26. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985 Oct; 142(10): 1137-5
27. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986 Dec; 143(12): 1587-0
28. Adityanjee. The spectrum concept and prevalence of neuroleptic malignant syndrome. Am J Psychiatry 1988 Aug; 145(8): 1041
29. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992 Feb; 53(2): 56-2
30. Adityanjee, Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neurolpetic malignant syndrome. Int J Neuropsychopharmacol 1999; 2: 129-4 CrossRef
31. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994 Mar; 182(3): 168-3 CrossRef
32. Duggal HS. Possible neuroleptic malignant syndrome associated ith paliperidone. J Neuropsychiatry Clin Neurosci 2007; 19(4): 477- CrossRef
33. Jaan MW, Grimsley SR, Gray EC, et al. Pharamacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24(2): 161-6 CrossRef
34. Pope Jr HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986 Aug; 174(8): 493- CrossRef
35. Blum A, Mauruschat W. Temperaturanstiege und Bluteiweiβver?nderungen unter der Therapie mit Neuroleptika-unter besonderer berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin. Pharmakopsychiatrie 1972; 5: 155-9 CrossRef
36. Nitenson NC, Kando JC, Frankenburg FR, et al. Fever associated with clozapine administration. Am J Psychiatry 1995 Jul; 152(7): 1102
37. Thornberg SA, Ereshefsky L. Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 1993 Sep–Oct; 13(5): 510-
38. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992; 63(1): 51-0 CrossRef
39. Caroff SN, Mann SC, Campbell EC. Atypical anti-psychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000; 30(5): 314-1
40. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003 Jan; 2(1): 21-5 CrossRef
41. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004 Apr; 65(4): 464-0 CrossRef
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
43. Ferioli V, Manes A, Melloni C, et al. Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief treatment with dantrolene. Can J Psychiatry 2004 Jul; 49(7): 497-
44. Corallo CE, Ernest D. Atypical neuroleptic malignant syndrome with long-term clozapine. Crit Care Resusc 2007 Dec; 9(4): 338-0
45. Skarpathiotakis M, Westreich N. NMS after clozapine initiation. J Am Acad Child Adolesc Psychiatry 2005 Nov; 44(11): 1101- CrossRef
46. Gambassi G, Capurso S, Tarsitani P, et al. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res 2006 Jun; 18(3): 266-0
47. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry 1998 Dec; 32(6): 884- CrossRef
48. Filice GA, McDougall BC, Ercan-Fang N, et al. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother 1998 Nov; 32(11): 1158- CrossRef
49. Hanel RA, Sandmann MC, Kranich M, et al. Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine. Arq Neuropsiquiatr 1998 Dec; 56(4): 833- CrossRef
50. Moltz DA, Coeytaux RR. Case report: possible neuroleptic malignant syndrome associated with olanzapine. J Clin Psychopharmacol 1998 Dec; 18(6): 485- CrossRef
51. Emborg C. Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskr Laeger 1999 Mar 8; 161(10): 1424-
52. Mujica R, Weiden P. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. Am J Psychiatry 2001 Apr; 158(4): 650- CrossRef
53. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome: a case. Hum Psychopharmacol 2003 Jun; 18(4): 301- CrossRef
54. Hall RCW, Appleby B, Hall RCW. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005 Jan; 98(1): 114- CrossRef
55. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatrica Scandinavica 2005 Sep; 112(3): 238-0, discussion 40 CrossRef
56. Reeves RR, Torres RA, Liberto V, et al. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 2002 May; 22(5): 641- CrossRef
57. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2002 Jun; 26(5): 897-02 CrossRef
58. Stevens DL, Lee MR, Padua Y. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy. Pharmacotherapy 2008 Mar; 28(3): 403- CrossRef
59. Warwick TC, Moningi V, Jami P, et al. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine. Nat Clin Pract Neurol 2008 Mar; 4(3): 170- CrossRef
60. Mishra B, Mishra B, Sahoo S, et al. Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine. Indian J Med Sci 2007 Oct; 61(10): 570- CrossRef
61. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994 Oct 29; 344(8931): 1228- CrossRef
62. Bajjoka I, Patel T, O’Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med 1997 Nov; 30(5): 698-00 CrossRef
63. Bonwick RJ, Hopwood MJ, Morris PL. Neuroleptic malignant syndrome and risperidone: a case report. Aust N Z J Psychiatry 1996 Jun; 30(3): 419-1 CrossRef
64. Dave M. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 1995 Aug; 152(8): 1233-
65. Gleason PP, Conigliaro RL. Neuroleptic malignant syndrome with risperidone. Pharmacotherapy 1997 May–Jun; 17(3): 617-1
66. Raitasuo V, Vataja R, Elomaa E. Risperidone-induced neuroleptic malignant syndrome in young patient. Lancet 1994 Dec 17; 344(8938): 1705 CrossRef
67. Kern JL, Cernek PK. Delayed risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996 Mar; 30(3): 300
68. Lee MS, Lee HJ, Kim L. A case of delayed NMS induced by risperidone. Psychiatr Serv 2000 Feb; 51(2): 254- CrossRef
69. Levin GM, Lazowick AL, Powell HS. Neuroleptic malignant syndrome with risperidone. J Clin Psychopharmacol 1996 Apr; 16(2): 192- CrossRef
70. Murray S, Haller E. Risperidone and NMS? Psychiatr Serv 1995 Sep; 46(9): 951
71. Najara JE, Enikeev ID. Risperidone and neuroleptic malignant syndrome: a case report. J Clin Psychiatry 1995 Nov; 56(11): 534-
72. Newman M, Adityanjee, Jampala C. Atypical neuroleptic malignant syndrome associated with risperidone treatment. Am J Psychiatry 1997 Oct; 154(10): 1475
73. Robb AS, Chang W, Lee HK, et al. Case study: risperidone-induced neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol 2000; 10(4): 327-0 CrossRef
74. Sechi G, Agnetti V, Masuri R, et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol. Biol Psychiatry 2000 Aug; 24(6): 1043-1 CrossRef
75. Sharma R, Trappler B, Ng YK, et al. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996 Jul–Aug; 30(7-): 775-
76. Singer S, Richards C, Boland RJ. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 1995 Aug; 152(8): 1234
77. Swanson Jr CL, Price WA, McEvoy JP. Effects of concomitant risperidone and lithium treatment. Am J Psychiatry 1995 Jul; 152(7): 1096
78. Tarsy D. Risperidone and neuroleptic malignant syndrome. JAMA 1996 Feb 14; 275(6): 446 CrossRef
79. Meterissian GB. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 1996 Feb; 41(1): 52-
80. Zalsman G, Lewis R, Konas S, et al. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 2004 Apr–Jun; 16(2): 179-2 CrossRef
81. Vercammen L, Buyse GM, Proost JEF, et al. Neuroleptic malignant syndrome in juvenile neuronal ceroid lipo-fuscinosis associated with low-dose risperidone therapy. J Inherit Metab Dis 2003; 26(6): 611- CrossRef
82. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel anti-psychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997 Feb 19; 321(1): 105-1 CrossRef
83. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuro-psychopharmacology 1999 Jun; 20(6): 612-7 CrossRef
84. Ali S, Pearlman RL, Upadhyay A, et al. Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Clin Psychopharmacol 2006 Aug; 26(4): 434- CrossRef
85. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004 Nov; 19(6): 351- CrossRef
86. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 2005 Feb; 162(2): 397- CrossRef
87. Hammerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole. J Am Acad Child Adolesc Psychiatry 2006 Jun; 45(6): 639-1 CrossRef
88. Kang S-G, Lee H-J, Lee M-S, et al. Atypical neuroleptic malignant syndrome associated with aripiprazole. J Clin Psychopharmacol 2006 Oct; 26(5): 534 CrossRef
89. Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007 Jan–Feb; 30(1): 47-1 CrossRef
90. Rodriguez OP, Dowell MS. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. J Okla State Med Assoc 2006 Jul–Aug; 99(7): 435-
91. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 2004 Dec; 43(12): 1457- CrossRef
92. Srephichit S, Sanchez R, Bourgeois JA. Neuroleptic malignant syndrome and aripiprazole in an antipsychoticnaive patient. J Clin Psychopharmacol 2006 Feb; 26(1): 94- CrossRef
93. Brunelle J, Guigueno S, Gouin P, et al. Aripiprazole and neuroleptic malignant syndrome. J Clin Psychopharmacol 2007 Apr; 27(2): 212- CrossRef
94. Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report 2. Prim Care Companion J Clin Psychiatry 2007; 9(2): 148- CrossRef
95. Fischman AJ, Bonab AA, Babich JW, et al. Positron emission tomographic analysis of central 5-hydroxy-tryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996 Nov; 279(2): 939-7
96. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995 Oct; 275(1): 101-3
97. Schmidt AW, Lebel LA, Howard Jr HR, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001 Aug 17; 425(3): 197-01 CrossRef
98. Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone. J Clin Psychopharmacol 2002 Dec; 22(6): 624- CrossRef
99. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother 2006 Jan; 40(1): 139-2 CrossRef
100. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson’s disease: a diagnostic challenge. Hum Psychopharmacol 2004 Apr; 19(3): 205- CrossRef
101. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004 Jul; 26(7): 1105- CrossRef
102. Ozen ME, Yumru M, Savas HA, et al. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007; 8(1): 42- CrossRef
103. Pandya M, Pozuelo L. A malignant neuroleptic spectrum: of diagnostic criteria and treatment implications in three case reports. Int J Psychiatry Med 2004; 34(3): 277-5 CrossRef
104. Strawn JR. Aripiprazole and the neuroleptic malignant yndrome. Schizophr Res 2006 Jul; 85(1-): 298- CrossRef
105. Yang SH, McNeely MJ. Rhabdomyolysis pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002 Aug; 159(8): 1435 CrossRef
106. Vito J, Jummani R, Coffey B. Advanced pediatric psychopharmacology. J Child Adolesc Psychopharmacol 2006 Aug; 16(4): 498-02 CrossRef
107. Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001; 61(14): 2123-0 CrossRef
108. Atbasoglu EC, Ozguven HD, Can Saka M, et al. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry 2004 Dec; 65(12): 1724- CrossRef
109. Peritogiannis V, Tsouli S, Pappas D, et al. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol 2007 Jul–Aug; 30(4): 245-
110. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004 Mar; 37Suppl. 1: S54-4
111. Gallarda T, Olie JP. Neuroleptic malignant syndrome in a 72-year-old man with Alzheimer’s disease: a case report and of the literature. Neuropsychopharmacology 2000; 10 Suppl. 3: S357
112. Abay E, Kose R. Amisulpride-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci 2007; 19(4): 488- CrossRef
113. Whalley N, Diaz PL, Howard J. Neuroleptic malignant syndrome associated with the use of quetiapine. Can J Hosp Pharmacy 1999; 52: 112
114. al-Waneen R. Neuroleptic malignant syndrome associated with quetiapine. Can J Psychiatry 2000 Oct; 45(8): 764-
115. Bora E, Saffet Gonul A, Akdeniz F, et al. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. Eur Psychiatry 2003 Oct; 18(6): 323 CrossRef
116. Bourgeois JA, Babine S, Meyerovich M, et al. A case of neuroleptic malignant syndrome with quetiapine. J Neuropsychiatry Clin Neurosci 2002; 14(1): 87 CrossRef
117. Chungh D-S, Kim B-N, Cho S-C. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005 Jul; 19(4): 422- CrossRef
118. Grignon S, Brethes JI, Chamberland M, et al. Incipient neuroleptic malignant syndrome with quetiapine/ paroxetine combination treatment: atypical presentation and early, successful rechallenge with olanzapine. Int J Psychiatry Clin Pract 2005; 9(4): 296- CrossRef
119. Sing KJ, Ramaekers GMGI, Van Harten PN. Neuroleptic malignant syndrome and quetiapine [published erratum appears in Am J Psychiatry 2002 May; 159(5): 892]. Am J Psychiatry 2002 Jan; 159(1): 149-0 CrossRef
120. Solomons K. Quetiapine and neuroleptic malignant syndrome. Can J Psychiatry 2002 Oct; 47(8): 791
121. Stanley AK, Hunter J. Possible neuroleptic malignant syndrome with quetiapine. Br J Psychiatry 2000 May; 176: 497 CrossRef
122. Sugden SG, Bourgeois JA, Kile SJ, et al. Neuroleptic malignant syndrome with dermatologic complications. J Clin Psychopharmacol 2004 Dec; 24(6): 676- CrossRef
123. Hatch CD, Lund BC, Perry PJ. Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics. Pharmacotherapy 2001 Aug; 21(8): 1003- CrossRef
124. Matsumoto R, Kitabayashi Y, Nakatomi Y, et al. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 2005 Apr; 162(4): 812 CrossRef
125. Precourt A, Dunewicz M, Gregoire G, et al. Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Ann Pharmacother 2005 Jan; 39(1): 153- CrossRef
126. Kobayashi A, Kawanishi C, Matsumura T, et al. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report. Prog Neuro-psychopharmacol Biol Psychiatry 2006 Aug 30; 30(6): 1170- CrossRef
127. Suzuki K, Awata S, Nakagawa K, et al. Catatonic stupor during the course of Parkinson’s disease resolved with electroconvulsive therapy. Mov Disord 2006 Jan; 21(1): 123- CrossRef
128. Coward DM, Imperato A, Urwyler S, et al. Biochemical and behavioural properties of clozapine. Psychopharmacology 1989; 99 Suppl.: S6-2 CrossRef
129. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993 Jan; 77(1): 185-02
130. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005 Jun 30; 135(3): 249-6 CrossRef - 作者单位：Dr Julian N. Trollor (1)
Xiaohua Chen (2)
Perminder S. Sachdev (1) (2)
1. School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia
2. Neuropsychiatric Institute, Euroa Centre, The Prince of Wales Hospital, Barker St, Randwick, New South Wales, 2031, Australia - ISSN：1179-1934
文摘
Neuroleptic malignant syndrome (NMS) is a rare but potentially severe idiosyncratic adverse reaction usually seen in the context of treatment with antipsychotic drugs. Although NMS is historically associated with the classic or ‘typical-antipsychotic drugs, it is also a potential adverse effect of atypical antipsychotic drugs. The widespread use of atypical antipsychotic drugs highlights the need to examine the data relating to the symptomatology, diagnosis, classification and management of NMS with these newer agents. We used MEDLINE and EMBASE to identify NMS case reports and systematic reviews published to June 2008 related to the atypical antipsychotic drugs clozapine, olanzapine, risperidone, paliperidone, aripiprazole, ziprasidone, amisulpride and quetiapine. Case reports and reviews were systematically examined. Our review suggests that, in general, NMS associated with atypical antipsychotic drugs manifests in a typical manner. One notable exception is clozapine-induced NMS, which appears less likely to manifest with extra-pyramidal features, including rigidity and tremor. The available literature highlights the divergence of opinion relating to the core diagnostic features of NMS and its conceptualization as a categorical versus dimensional disorder. Both these issues have relevance for the identification of atypical or milder forms of NMS, which are sometimes seen with atypical antipsychotic drugs.